MHC Class I Antigens In Malignant Cells
Aptsiauri, Natalia.
MHC Class I Antigens In Malignant Cells Immune Escape And Response To Immunotherapy / [electronic resource] : by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera. - VIII, 51 p. 17 illus., 14 illus. in color. online resource. - SpringerBriefs in Cancer Research ; 6 . - SpringerBriefs in Cancer Research ; 6 .
Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. .
9781461465430
10.1007/978-1-4614-6543-0 doi
Medicine.
Cancer research.
Immunology.
Molecular biology.
Biomedicine.
Cancer Research.
Immunology.
Molecular Medicine.
RC261-271
614.5999
MHC Class I Antigens In Malignant Cells Immune Escape And Response To Immunotherapy / [electronic resource] : by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera. - VIII, 51 p. 17 illus., 14 illus. in color. online resource. - SpringerBriefs in Cancer Research ; 6 . - SpringerBriefs in Cancer Research ; 6 .
Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion.
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. .
9781461465430
10.1007/978-1-4614-6543-0 doi
Medicine.
Cancer research.
Immunology.
Molecular biology.
Biomedicine.
Cancer Research.
Immunology.
Molecular Medicine.
RC261-271
614.5999